Teleflex Incorporated

NYSE:TFX

Medical - Instruments & Supplies

Healthcare
$165.85 +0.83%

+$1.04 today

Market cap
$6.58B
Beta
0.82
P/E (TTM)
-5.5
EPS (TTM)
-$22.79
Dividend yield
1.08%
52W Low $100.18High $139.67

Volume 1.16M

Average 0.80M

TFX Interest Expense

Cost of servicing the company's debt during the period.

Teleflex IncorporatedNYSE: TFX

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense grows, but more slowly than its trailing trend

Q2 FY2026 interest expense of $27.95M rose 28.8% year over year, behind the +49.4% change in trailing-twelve-month interest expense. Sequentially, it rose 8.7% from the prior quarter. Over 3 fiscal years it compounded at +22.7% a year.

Context

  • Interest expense amounted to 5.0% of revenue in FY2025, up 2.3 pp from a year earlier.
  • Interest expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +28.8% toward the trailing-twelve-month pace of +49.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$27.95M+8.7% QoQ
Last fiscal yearDec 2025
$100.22M+20.0% YoY
LTMJun 2026
$119.43M+49.4% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.8%——
1 year+20.0%——
3-year CAGR+22.7%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
100.22M USD
Year-over-year change
+20.0%
4-year CAGR
+15.2%

Interest Expense vs competitors

How TFX compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +49.4% is the 3rd highest of 8, against a peer median of +23.8%.
  • Interest expense amounts to 4.6% of revenue for TFX, versus a peer median of 4.9%.
TFX Competitors
Interest Expense for TFX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$396M USD-7.0%+43.5%7.4%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$185.29M USD+25.9%+18.8%18.4%
TFXTeleflex IncorporatedLTM Jun 2026$119.43M USD+49.4%+22.7%4.6%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$93.71M USD+4.9%+72.3%20.8%
ALKSAlkermes plcLTM Sep 2026$86.65M USD+1764.1%-2.0%4.9%
TGTXTG Therapeutics, Inc.LTM Sep 2026$46.59M USD+70.9%+37.9%5.2%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$17.68M USD-37.1%+61.0%1.1%
STVNStevanato Group S.p.A.LTM Jun 2026€9.5M EUR+23.8%+76.9%0.8%
PCVXVaxcyte, Inc.LTM Jun 2026$0 USD———
KRYSKrystal Biotech, Inc.LTM Jun 2026$0 USD——0.0%
CRSPCRISPR Therapeutics AGLTM Sep 2026$0 USD——0.0%
Peer median (excluding TFX) —+23.8%+43.5%4.9%

Competitors are the stored peer set for TFX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.81B2.79B2.97B3.05B1.99B
Cost of Revenue1.26B1.26B1.33B1.34B871.96M
Gross Profit1.55B1.53B1.65B1.7B1.12B
Gross Margin55.2%54.9%55.4%55.9%56.2%
Research & Development130.84M153.82M154.35M161.67M144.78M
Selling, General & Admin860.09M863.75M929.87M995.27M720.17M
Operating Expenses921.51M1.03B1.14B1.55B864.95M
Depreciation & Amortization237.36M230.59M242.12M274.6M177.74M
EBITDA853.8M730.77M761.21M433.62M302.51M
EBITDA Margin30.4%26.2%25.6%14.2%15.2%
Operating Income628.1M499.73M506.31M151.01M255.8M
Operating Margin22.4%17.9%17.0%5.0%12.8%
Interest Income1.33M912K12.78M8.01M6.4M
Interest Expense56.97M54.26M85.08M83.54M100.22M
Other Income / Expenses(68.63M)(53.81M)(72.3M)(75.54M)(231.25M)
Income Before Tax559.47M445.92M434.01M75.48M24.55M
Pre-Tax Margin19.9%16.0%14.6%2.5%1.2%
Income Tax Expense74.35M83M76.44M5.32M(33.98M)
Net Income485.37M363.14M356.33M69.68M(905.64M)
Net Margin17.3%13.0%12.0%2.3%-45.4%
EPS (Basic)10.387.747.581.49(20.30)
EPS (Diluted)10.237.687.531.48(20.25)
Weighted Avg Shares46.77M46.9M46.98M46.84M44.62M
Weighted Avg Shares (Diluted)47.43M47.31M47.3M47.09M44.72M

Teleflex Incorporated

NYSE:TFX

Intrinsic Alpha fair value

Locked

Current Price

$165.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.